

0310



I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to U S Patent and Trademark Office, Box Sequence, P O Box 2327, Arlington, VA 22202

Date of Signature  
and Deposit:

May 23, 2002

Richard T. Roche, Reg. No. 38,599

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Adrien R. Beaudoin *et al.*  
Serial No.: 09/781,796  
Filed: February 12, 2001  
For: ATP-Diphosphohydrolases, Process of Purification Thereof  
and Process of Producing Thereof by Recombinant Technology  
Group Art Unit: 1651  
Docket Number: 920333.90019

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

**TRANSMITTAL LETTER**

Dear Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed March 27, 2002 in the above-identified application, Applicants enclose: (1) a Statement under 37 CFR 1.821(g) and attached amended Sequence Listing; and (2) a copy of the Sequence Listing in computer readable format.

No fees are believed to be due. If any fees are due, please charge them to Deposit Account 17-0055.

Respectfully submitted,

Adrien R. Beaudoin *et al.*

Dated: May 23, 2002

By:

Richard T. Roche  
Reg. No.: 38,599  
QUARLES & BRADY LLP  
411 East Wisconsin Avenue  
Milwaukee, WI 53202  
(414) 277-5805

02-Apr-10 13:45

FROM: GOUDEAU GAGE DUBUC

+ 093817401 02/04 4-3902



MAY 29 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY/AGENT NUMBER
09/781,796	02/12/2001	Adrien R. Beaudoin	920333 90019

25545  
GOUDEAU GAGE DUBUC  
800 PLACE VICTORIA, SUITE 3400  
MONTREAL, QUEBEC, H4Z 1E9  
CANADA

CONFIRMATION NO. 6953

FORMALITIES LETTER



\*OC000000007726055\*

Date Mailed 03/27/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

APR 10 '02 12:48

+

PAGE.02